NCT07119905

Brief Summary

The goal of this observational study is to investigate the potential association between MMP-9 gene polymorphism and susceptibility to Primary Open Angle Glaucoma development in Egyptian patients The main question it aims to

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
80

participants targeted

Target at P50-P75 for all trials

Timeline
8mo left

Started Jun 2026

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 2, 2025

Completed
11 days until next milestone

First Posted

Study publicly available on registry

August 13, 2025

Completed
10 months until next milestone

Study Start

First participant enrolled

June 1, 2026

Expected
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2027

1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2027

Last Updated

August 13, 2025

Status Verified

August 1, 2025

Enrollment Period

7 months

First QC Date

August 2, 2025

Last Update Submit

August 6, 2025

Conditions

Keywords

Primary Open Angle GlaucomaPOAGGene PolymorphismMMP-9Matrix Metalloproteinase-9 Gene Polymorphism

Outcome Measures

Primary Outcomes (1)

  • Matrix metalloproteinase-9 gene polymorphism

    Matrix metalloproteinase-9 gene polymorphism by polymerase chain reaction

    14 months

Study Arms (2)

Control Group

Normal healthy volunteers aged \> 30 years

Genetic: genotyping assay by polymerase chain reaction

Experimental Group

Patients aged \>30 years and diagnosed with Primary Open Angle Glaucoma

Genetic: genotyping assay by polymerase chain reaction

Interventions

Blood sample will be obtained from all participants by withdrawing 3 mL of blood via venipuncture in ethylenediaminetetraacetic acid tube. Thereafter, DNA extraction will be obtained after centrifugation to be used for genotyping assay of MMP-9 gene with polymerase chain reaction

Control GroupExperimental Group

Eligibility Criteria

Age30 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients with Primary Open Angle Glaucoma in Department of ophthalmology in Sohag University Hospitals and healthy controls of matched age and sex

You may qualify if:

  • Men and women older than 30 years
  • Primary open angle glaucoma as evidenced from characteristic visual field loss and optic disc cupping (POAG group)
  • Healthy subjects matched by age, sex and ethnicity to the POAG patients group (control group)

You may not qualify if:

  • Exfoliation glaucoma, pigmentary glaucoma
  • History of acute angle closure

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sohag University Hosipital

Sohag, Sohag Governorate, 82525, Egypt

Location

Related Publications (3)

  • Grzybowski A, Och M, Kanclerz P, Leffler C, Moraes CG. Primary Open Angle Glaucoma and Vascular Risk Factors: A Review of Population Based Studies from 1990 to 2019. J Clin Med. 2020 Mar 11;9(3):761. doi: 10.3390/jcm9030761.

    PMID: 32168880BACKGROUND
  • Liu Y, Allingham RR. Major review: Molecular genetics of primary open-angle glaucoma. Exp Eye Res. 2017 Jul;160:62-84. doi: 10.1016/j.exer.2017.05.002. Epub 2017 May 10.

    PMID: 28499933BACKGROUND
  • Zhao F, Fan Z, Huang X. Role of matrix metalloproteinase-9 gene polymorphisms in glaucoma: A hospital-based study in Chinese patients. J Clin Lab Anal. 2020 Mar;34(3):e23105. doi: 10.1002/jcla.23105. Epub 2019 Nov 12.

    PMID: 31713905BACKGROUND

MeSH Terms

Conditions

Glaucoma, Open-Angle

Condition Hierarchy (Ancestors)

GlaucomaOcular HypertensionEye Diseases

Central Study Contacts

Thomas Talaat Nageh, Demonstrator

CONTACT

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Demonstrator

Study Record Dates

First Submitted

August 2, 2025

First Posted

August 13, 2025

Study Start (Estimated)

June 1, 2026

Primary Completion (Estimated)

January 1, 2027

Study Completion (Estimated)

February 1, 2027

Last Updated

August 13, 2025

Record last verified: 2025-08

Locations